Legend Biotech director files initial Form 3

Legend Biotech Corp director Zhang Fangliang filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 06:54 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Legend Biotech Corp director Zhang Fangliang filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not list any specific share or option holdings and shows no recent insider transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Zhang Fangliang's Form 3 filing for LEGN show?

The Form 3 for Legend Biotech Corp shows that Zhang Fangliang is an insider, serving as a director. The filing does not report any specific share or option holdings and includes no recent insider transactions.

Are there any buy or sell transactions in the LEGN Form 3?

No, the Form 3 for Legend Biotech Corp reports no insider buy or sell activity. Transaction counts and share amounts for purchases, sales, exercises, gifts, and tax withholdings are all shown as zero.

What insider role does Zhang Fangliang hold at Legend Biotech Corp (LEGN)?

Zhang Fangliang is identified as a director of Legend Biotech Corp. He is not listed as an officer and is not marked as a ten percent owner in this Form 3 filing.

Does the LEGN Form 3 disclose any derivative positions or options?

The Form 3 indicates no derivative positions or options for Zhang Fangliang. The derivative summary is empty, and exercise-related counts and shares are all reported as zero in the filing.

Does the Legend Biotech (LEGN) Form 3 indicate significant ownership?

The Form 3 does not quantify any share or option holdings for Zhang Fangliang. It simply records his status as a director and insider without providing specific ownership amounts or percentages.

Are there any special footnote disclosures in the LEGN Form 3?

The Form 3 includes a footnote field but provides no substantive text. There are no additional disclosures about voting power, related entities, or trading plans in the available information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zhang Fangliang

(Last)

(First)

(Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET

08873

(City)

(State)

(Zip)

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR